abstract |
The invention generally relates in part to methods of reducing hepatobiliary dysfunction and reducing risk of incident hepatobiliary dysfunction, comprising administering a MetAP2 inhibitor to patients in need thereof. The invention also relates in part to methods of effecting weight loss while reducing hepatic injury or risk thereof, comprising administering a MetAP2 inhibitor. |